Preparation and in vitro evaluation of vaginal formulations including siRNA and paclitaxel-loaded SLNs for cervical cancer

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 109, Issue , 2016, Pages 174-183

  Büyükköroğlu, Gülay ^a   Şenel, Behiye ^a   Başaran, Ebru ^a   Yenilmez, Evrim ^a   Yazan, Yasemin ^a  

^a ANADOLU UNIVERSITY   (Turkey)

Author keywords

Bcl 2 siRNA; Cationic SLN; Paclitaxel; Vaginal suppository

Indexed keywords

MACROGOL 6000; PACLITAXEL; PROTEIN BCL 2; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; DRUG CARRIER; LIPID; LIPOSOME; NANOPARTICLE; SOLVENT; SUPPOSITORY;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PROTEIN DEPLETION; RNA STABILITY; UTERINE CERVIX CANCER; ZETA POTENTIAL; CHEMISTRY; COLORIMETRY; GENETICS; HELA CELL LINE; INTRAVAGINAL DRUG ADMINISTRATION; SUPPOSITORY; UTERINE CERVICAL NEOPLASMS;

ADMINISTRATION, INTRAVAGINAL; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORIMETRY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; LIPIDS; LIPOSOMES; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; SOLVENTS; SUPPOSITORIES; UTERINE CERVICAL NEOPLASMS;

EID: 84994227150     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2016.10.017     Document Type: Article

References (61)

1. [1] Urasa, M., Darj, E., Knowledge of cervical cancer and screening practices of nurses at a regional hospital in Tanzania. Afr. Health Sci. 11:1 (2011), 48–57.
2. [2] Volodko, N., Gordon, M., Salla, M., Ghazaleh, H.A., Baksh, S., RASSF tumor suppressor gene family: biological functions and regulation. FEBS Lett. 588 (2014), 2671–2684.
3. [3] Zhang, S., Zhao, B., Jıang, H., Wang, B., Ma, B., Cationic lipids and polymers mediated vectors for delivery of siRNA. J. Control. Release 123 (2007), 1–10.
4. [4] Xu, C., Wang, J., Delivery systems for sirna drug development in cancer therapy. Asian J. Pharm. Sci. 10 (2015), 1–12.
5. [5] Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001), 494–498.
6. [6] Tseng, Y.C., Mozumdar, S., Huang, L., Lipid-based systemic delivery of siRNA. Adv. Drug Deliver. Rev. 61 (2009), 721–731.
7. [7] Li, C.X., Parker, A., Menocal, E., Xiang, S., Borodyansky, L., Fruehauf, J.H., Delivery of RNA interference. Cell Cycle 5:18 (2006), 2103–2109.
8. [8] Takabatake, Y., Isaka, Y., Mizui, M., Kawachi, H., Takahara, S., Imai, E., Chemically modified siRNA prolonged RNA interference in renal disease. Biochem. Biophys. Res. Commun. 363:2 (2007), 432–437.
9. [9] Gary, D., Puri, N., Won, Y.Y., Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J. Control. Release 121 (2007), 64–73.
10. [10] Reischl, D., Zimmer, A., Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomed. Nanotech. Biol. Med. 5:1 (2009), 8–20.
11. [11] Gorbatyuk, M., Justilien, V., Liu, J., Hauswirth, W.W., Lewin, A.S., Suppression of mouse rhodopsin expression in vivo by AAV Mediated siRNA delivery. Vision. Res. 47:9 (2007), 1202–1208.
12. [12] Chen, G.X., Dong, Q.H., Zhang, J.W., Fu, F.F., Xu, Z.F., Liang, Q.Y., Zheng, S., Ding, J.Y., Knockdown of PLK1 mRNA by special siRNA. Yi Chuan 28:1 (2006), 21–25.
13. [13] Sioud, M., Sørensen, D.R., Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312:4 (2003), 1220–1225.
14. [14] Bouxsein, N.F., Mcallister, C.S., Ewert, K.K., Samuel, C.E., Safinya, R.C., Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA. Biochemistry 46:16 (2007), 4785–4792.
15. [15] Kataoka, K., Itaka, K., Nishiyama, N., Yamasaki, Y., Oishi, M., Nagasaki, Y., Smart polymeric micelles as nanocarriers for oligonucleotides and siRNA delivery. Nucleic Acids Symp. Ser. 49:1 (2005), 17–18.
16. [16] Katas, H., Alpar, H.O., Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release 115:2 (2006), 16–25.
17. [17] Savaese, A., Cognetti, F., New drugs in the treatment of recurrent or metastatic cervical cancer. Crit. Rev. Oncol. Hemat. 48 (2003), 323–327.
18. [18] Wu, J., Liu, Q., Lee, R.J., A folate receptor-targeted liposomal formulation for paclitaxel. Int. J. Pharm. 316 (2006), 148–153.
19. [19] Thu, T.H., Dass, C.R., Dunstan, D.E., Injectable chitosan hydrogels for localised cancer therapy. J. Control. Release 126 (2008), 205–216.
20. [20] Chimmiri, P., Rajalakshmi, R., Mahitha, B., Ramesh, G., Noor Ahmed, V.H., Solid lipid nanoparticles: a novel carrier for cancer therapy. Int. J. Pharm. Biol. Sci. 3:3 (2012), 405–413.
21. [21] Serpea, L., Catalano, M.G., Cavalli, R., Ugazio, E., Bosco, O., Canaparo, R., Muntoni, E., Frairia, R., Gasco, M.R., Eandi, M., Zara, G.P., Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm. 58 (2004), 673–680.
22. [22] Shah, R., Eldridge, D., Palombo, E., Harding, I., Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J. Phys. Sci. 25:1 (2014), 59–75.
23. [23] Banerjee, I., De, K., Mukherjee, D., Dey, G., Chattopadhyay, S., Mukherjee, M., Mandal, M., Bandyopadhyay, A.K., Gupta, A., Ganguly, S., Misra, M., Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy. Acta Biomater. 38 (2016), 69–81.
24. [24] Yu, Y.H., Kim, E., Park, D.E., Shim, G., Lee, S., Kim, Y.B., Kim, C.W., Oha, Y.K., Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur. J. Pharm. Biopharm. 80 (2012), 268–273.
25. [25] Pavelić, Z., Skalko-Basnet, N., Filipović-Grcić, J., Martinac, A., Jalsenjak, I., Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J. Control. Release 106 (2005), 34–43.
26. [26] Hussain, A., Ahsan, F., The vagina as a route for systemic drug delivery. J. Control. Release 103 (2005), 301–313.
27. [27] Dobaria, N., Mashru, R., Vadia, N.H., Vaginal drug delivery systems: a review of current status. East Cent Afr. J. Pharm. Sci. 10 (2007), 3–13.
28. [28] Choudhury, A., Das, S., Kar, M., A review on novelty and potentiality of vaginal drug delivery. Int. J. Pharm.Tech. Res. 3:2 (2011), 1033–1044.
29. [29] Haas, S., Woerdenbag, H., Sznitowska, M., Rectal and vaginal. Bouwman-Boer, Fenton-May, Brun, (eds.) Practical Pharmaceutics: An International Guideline for the Preparation, Care and Use of Medicinal Products, 2015, Springer International Publishing AG, Switzerland, 190–225.
30. [30] Şenel, B., Büyükköroğlu, G., Yazan, Y., Solid lipid and chitosan particulate systems for delivery of siRNA. Pharmazie 8 (2015), 698–705.
31. [31] Sun, B., Ranganathan, B., Feng, S.S., Multifunctional poly (D, L-lactide-coglycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29 (2008), 475–486.
32. [32] Büyükköroğlu, G., Yazan, E.Y., Öner, A.F., Preparation and physicochemical characterizations of solid lipid nanoparticles containing DOTAP® for DNA delivery. Turk. J. Chem. 39 (2015), 1012–1024.
33. [33] Singha, K., Namgung, R., Kim, W.J., Polymers in small-interfering RNA delivery. Nucleic Acid Ther. 21:3 (2011), 133–147.
34. [34] Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity tests. J. Immunol. Methods 63 (1983), 55–63.
35. [35] Desjardins, P., Hansen, J.B., Allen, M., Microvolume protein concentration determination using the NanoDrop 2000c spectrophotometer. J. Vis. Exp., 33, 2009, 1610.
36. [36] Neves, J., Amaral, M.H., Bahia, M.F., Performance of an in vitro mucoadhesion testing method for vaginal semisolids: influence of different testing conditions and instrumental parameters. Eur. J. Pharm. Biopharm. 69 (2008), 622–632.
37. [37] Owen, D.H., Katz, D.F., A vaginal fluid simulant. Contraception 59 (1999), 91–95.
38. [38] Lai, S.K., O'Hanlon, D.E., Harrold, S., Man, S.T., Wang, Y.Y., Cone, R., Hanes, J., Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. PNAS 104:5 (2007), 1482–1487.
39. [39] Neves, J., Nunes, R., Machado, A., Sarmento, B., Polymer-based nanocarriers for vaginal drug delivery. Adv. Drug Deliver. Rev. 92 (2015), 53–70.
40. [40] Prabhakar, K., Afzal, S.M., Surender, G., Kishann, V., Tween 80 containing lipid nanoemulsions for delivery of indinavir to brain. Acta Pharmaceutica Sinica B 3:5 (2013), 345–353.
41. [41] Kaur, I.P., Bhandari, R., Bhandari, S., Kakkar, V., Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 127 (2008), 97–109.
42. [42] Soutoa, E.B., Wissinga, S.A., Barbosa, C.M., Müller, R.H., Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 278:1 (2004), 71–77.
43. [43] Vighi, E., Ruozi, B., Montanari, M., Battini, R., Leo, E., PDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles. Int. J. Pharm. 389 (2010), 254–261.
44. [44] Carrillo, C., Sánchez-Hernández, N., García-Montoya, E., Pérez-Lozano, P., Suñé-Negre, J.M., Ticó, J.R., Suñé, C., Miñarro, M., DNA delivery via cationic solid lipid nanoparticles (SLNs). Eur. J. Pharm. Sci. 49 (2013), 157–165.
45. [45] Wu, C., Wang, L., Harbottle, D., Masliyah, J., Xu, Z., Studying bubble–particle interactions by zeta potential distribution analysis. J. Colloid Interface Sci. 449 (2015), 399–408.
46. [46] Caramella, C.M., Rossi, S., Ferrari, F., Bonferoni, M.C., Sandri, G., Mucoadhesive and thermogelling systems for vaginal drug delivery. Adv. Drug Deliver. Rev. 92 (2015), 39–52.
47. [47] Belletti, D., Tosi, G., Forni, F., Lagreca, I., Barozzi, P., Pederzoli, F., Vandelli, M.A., Riva, G., Luppi, M., Ruozi, B., PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity. Eur. J. Pharm. Biopharm. 99 (2016), 7–17.
48. [48] Gagnon, Z., Senapati, S., Gordon, J., Chang, H.C., Dielectrophoretic detection and quantification of hybridized DNA molecules on nano-genetic particles. Electrophoresis 29 (2008), 4808–4812.
49. [49] Yadav, D., Anwar, M.F., Garg, V., Kardam, H., Beg, M.N., Suri, S., Gaur, S., Asif, M., Development of polymeric nanopaclitaxel and comparison with free paclitaxel for effects on cell proliferation of MCF-7 and B16F0 carcinoma cells. Asian Pac. J. Cancer Prev. 15:5 (2014), 2335–2340.
50. [50] Gvili, K., Benny, O., Danino, D., Machluf, M., Poly(D,L-lactide-coglycolide acid) nanoparticles for DNA delivery: waiving preparation complexity and increasing efficiency. Biopolymers 85 (2006), 379–391.
51. [51] Mehnert, W., Mäder, K., Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliver. Rev. 47:2–3 (2001), 165–196.
52. [52] Hong, J., Huang, Y., Li, J., Yi, F., Zheng, J., Huang, H., Wei, N., Shan, Y., An, M., Zhang, H., Ji, J., Zhang, P., Xi, Z., Du, Q., Liang, Z., Comprehensive analysis of sequence-specific stability of siRNA. FASEB J. 24 (2010), 4844–4855.
53. [53] Jafari, M., Xu, W., Pan, R., Sweeting, C.M., Karunaratne, D.N., Chen, P., Serum stability and physicochemical characterization of a novel amphipathic peptide C6M1 for siRNA delivery. PLoS ONE 9:5 (2014), 1–9.
54. [54] Young, S.W.S., Stenzel, M., Yang, J., Nanoparticle-siRNA: a potential cancer therapy?. Crit. Rev. Oncol. Hemat. 98 (2016), 159–169.
55. [55] Rao, N.M., Cationic lipid-mediated nucleic acid delivery: beyond being cationic. Chem. Phys. Lipids 163 (2010), 245–252.
56. [56] Lv, H., Zhang, S., Wang, B., Cui, S., Yan, J., Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114 (2006), 100–109.
57. [57] Creixell, M., Peppasa, N.A., Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 7 (2012), 367–379.
58. [58] Wang, S., Qiu, J., Shi, Z., Wang, Y., Chen, M., Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer. Biotechnol. Adv. 33 (2015), 224–241.
59. [59] das Neves, J., Bahia, M.F., Gels as vaginal drug delivery systems. Int. J. Pharm. 318 (2006), 1–14.
60. [60] Furst, T., Dakwar, G.R., Zagato, E., Lechanteur, A., Remaut, K., Evrard, B., Braeckmans, K., Piel, G., Freeze-dried mucoadhesive polymeric system containing pegylated lipoplexes: towards a vaginal sustained released system for siRNA. J. Control. Release 236 (2016), 68–78.
61. [61] Poelvoorde, N., Verstraelen, H., Verhelst, R., Saerens, B., De Backer, E., dos Santos Santiago, G.L., Vervaet, C., Vaneechoutte, M., De Boeck, F., Bortel, L.C., Temmerman, M., Remon, J.P., In vivo evaluation of the vaginal distribution and retention of a multi-particulate pellet formulation. Eur. J. Pharm. Biopharm. 73 (2009), 280–284.